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S U M M A R Y
Objectives: The aim of this study was to determine the epidemiology and clinical impact of infections in
patients awaiting heart transplantation.
Methods: We evaluated all patients considered for a heart transplant in our center over a period of 18
months over a period of 18 months from 2007 to 2009. The patients were followed up for 8 months or
until death, transplant, or loss to follow-up.
Results: Ninety patients were included in the study. During follow-up, 25 infections were recorded in 22
heart transplant candidates (24.4%). Respiratory infections were the most frequent infection (12
bronchitis; 48.0%), followed by skin and soft tissue infections (four infections; 16.0%), intra-abdominal
infections (four infectious diarrhea; 16.0%), bacteremia (three infections; 12.0%), and urinary tract
infections (two infections; 2.0%). Age, comorbidity, sex, and diabetes were not found to be risk factors for
infection. Twenty-four patients (26.7%) were transplanted during follow-up. Infection before
transplantation was not associated with an increased risk of mortality or a higher rate of infection
in the immediate post-transplant period.
Conclusions: Infections are common in heart transplant candidates, affecting almost 25% of them.
Respiratory tract infections are the most frequent type of infection. However, they are not associated
with increased mortality in the immediate post-transplant period.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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There are few reports on the incidence and types of infection in
patients with terminal heart failure, although the role of infection
in hospital admissions is well known in these patients.1 It is
recognized that post-transplant infectious morbidity in heart
transplant recipients is moderate,2–5 and there are many known
risk factors for infection in the early post-transplant period.4,6
Nevertheless, there are no communications describing the
epidemiology of infection in patients awaiting heart transplanta-
tion, and the impact of pre-transplant infection on the early post-
transplant period is not known.
The main aim of this study was to describe the frequency,
epidemiology, and risk factors for infection in patients awaiting
heart transplantation. Another objective was to determine the* Corresponding author. Tel./fax: +34 957 011636.
E-mail address: marcelinogonzalezpadilla@hotmail.com (M. Gonza´lez-Padilla).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.01.021inﬂuence of infection on waiting-list mortality and early mortality
and morbidity after transplantation.
2. Materials and methods
2.1. Study population and follow-up
Our institution is a tertiary care hospital that has had a heart
transplantation program since 1986. It is the reference center for
heart transplantation for a population of approximately two
million, and 542 heart transplants had been performed up until
2011.
Over a period of 18 months from 2007 to 2009, we prospectively
included all adult patients (over the age of 14 years) who were
considered for inclusion on the heart transplantation waiting list in
our center. The patients were followed up for 8 months from the
time they were evaluated, with clinical assessments performed at
least monthly. All episodes of bacterial and fungal infection
requiring either hospitalization or outpatient treatment wereses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics of patients included in the study (N = 90)
Age, years, mean  standard deviation 51.2  11.8
Sex, number of males (% males) 67 (74.4%)
Charlson comorbidity index,
mean  standard deviation
2.93  1.7
History of tobacco use, number of
patients who use tobacco/total
patients (%)
44 (48.9%)
Diabetes mellitus, number of diabetic
patients/total patients (%)
24 (26.6%)
Alcohol consumption, number of
patients with heavy alcohol
consumption/total patients (%)
10 (11.1%)
Treatment with corticoids or other
immunosuppressants at ﬁrst
evaluation
5 (5.6%)
Positive Toxoplasma IgG 45 (50.0%)
Positive Epstein–Barr virus IgG 78 (86.7%)
Positive cytomegalovirus IgG 75 (83.3%)
Follow-up time,a days,
mean  standard deviation
186.1  89.8
Underlying cardiopathy
Dilated 48 (53.3%)
Ischemic 24 (26.7%)
Congenital 10 (11.1%)
Hypertrophic 4 (4.4%)
Retransplant 1 (1.1%)
Other 3 (3.3%)
a Does not include post-transplant follow-up time (24.6  11.0 days).
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etiological diagnosis was made.
Initial follow-up ended at transplantation, death, or loss to
follow-up of the patient. Follow-up did not end if the patient was
excluded from the waiting list. Patients who were transplanted
were followed up for 1 month after transplantation.
2.2. Routine antibiotic prophylaxis after transplantation
Routine antibiotic prophylaxis after heart transplantation in
our center is performed with cloxacillin and cefotaxime and is
maintained for 5 days. Trimethoprim–sulfamethoxazole is initiat-
ed as soon as possible and maintained for the ﬁrst 3–6 months.
2.3. Classiﬁcation of episodes of infection
The infections were deﬁned according to internationally
accepted criteria recommended by organizations such as the
American Society of Transplantation,7 the Infectious Diseases
Society of America (IDSA),8–10 and the European Association for the
Study of the Liver.11 Infections were classiﬁed into the categories
listed below.
2.3.1. Respiratory tract infection
Proven and probable cases of pneumonia and acute bronchitis
were included in this category. A diagnosis of pneumonia was
made in the presence of one or more of the following symptoms:
cough, hemoptysis, fever, dyspnea, or pleuritic chest pain, in
addition to compatible ﬁndings on a radiograph or a thoracic
computerized tomography. The ﬁnal diagnosis was established
based on fulﬁllment of the above criteria as well as the presence of
a positive culture in a valid respiratory sample. Cases where no
organisms were isolated in respiratory samples were considered
probable pneumonia. In the presence of clinical criteria for lower
respiratory tract infection without radiological evidence of
consolidation, a diagnosis of bronchitis was made.8
2.3.2. Urinary tract infection
Conﬁrmed bacterial urinary tract infection (UTI) included cases
of cystitis and pyelonephritis with positive urine culture. Cystitis
was deﬁned by the presence of a urine bacteria count of more than
10 000 colony-forming units (cfu)/ml and pyuria (3 leukocytes
per high-power ﬁeld or positive leukocyte esterase), with clinical
manifestations such as dysuria, high frequency and/or urinary
urgency in the absence of pyelonephritis criteria.7 Pyelonephritis
was deﬁned by the presence of a positive urine culture (>10 000
cfu/ml) and pyuria in association with tenderness at the
costovertebral angle with fever and/or positive blood culture.7
Cases of asymptomatic bacteriuria, deﬁned as the presence of a
urine bacteria count of >10 000 cfu/ml without clinical manifesta-
tions of UTI, were not included.7
2.3.3. Bacteremia and catheter-related bacteremia
The diagnosis of bacteremia was made in the case of isolation of
a microorganism other than a skin contaminant (diphtheroids,
Bacillus spp, or coagulase-negative staphylococci) in one culture
and the presence of signs of infection (chills, fever, hypotension), or
the isolation of the above contaminants in two consecutive
cultures, with signs of infection.12 When there was a focus other
than catheter-related bacteremia, the episode of infection was
classiﬁed as organ infection. Bacteremia was considered to be
catheter-related if it met the criteria established by the IDSA.9
2.3.4. Intra-abdominal infection
This category included episodes of infectious diarrhea caused
by bacteria, spontaneous bacterial peritonitis, and cholangitis.‘Infectious diarrhea’ was deﬁned as diarrhea due to a bacterial
etiology, accompanied by symptoms of nausea, vomiting, or
abdominal cramps.10 Cholangitis was deﬁned as cases of fever,
right upper quadrant abdominal pain and cholestatic enzyme
abnormalities, and/or direct hyperbilirubinemia.7 Spontaneous
bacterial peritonitis was deﬁned as the presence of ascites and a
polymorphonuclear cell count of more than 0.25  109/l in ascitic
ﬂuid.11
2.3.5. Skin and soft tissue infections
All skin and soft tissue infections (including surgical site
infections) were included in this category regardless of their
location and extension. Non-necrotizing infections (impetigo,
erysipelas, cellulitis, or pyomyositis) and necrotizing infections
(necrotizing cellulitis or fascitis and myonecrosis) were included.
Infections secondary to bites, pressure ulcers, and diabetic foot
ulcers were also included.13 Surgical site infections (SSI) were
included in this category. SSI was deﬁned as infection of the skin,
independently of the depth of the infection, that occurred within
30 days after the operation if no implant was left in place, or within
1 year if the implant was left in place and the infection appeared to
be related to the operation.14
2.4. Mortality
All occurrences of death during follow-up were deﬁned as
‘crude mortality’. Deaths that could be directly attributed to an
infectious episode were deﬁned as ‘death due to infection’.
2.5. Statistical analysis
The Chi-square test or Fisher’s exact test was used to
compare the qualitative variables, while the Student’s t-test and
Mann–Whitney U-test were used to compare the quantitative
variables. To determine risk factors for infection and mortality
based on follow-up time, we used the Cox regression analysis.
Statistical signiﬁcance was considered when the p-value was
<0.05.
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Ninety patients were included during the study period. The
baseline characteristics of patients included in the study are shown
in Table 1. At the end of follow-up, 24 candidates were
transplanted (26.6% of those evaluated), ﬁve (5.5%) patients died
before transplantation, 14 (15.5%) patients remained on the
waiting list, and 47 (52.2%) patients had been excluded from the
active waiting list. No death could be directly attributed to an
infectious episode.
3.1. Waiting-list follow-up
During follow-up, 25 infections were recorded in 22 heart
transplant candidates (24.4%). Respiratory infections were the
most frequent infection (12 bronchitis; 48.0%), followed by skin
and soft tissues infections (four infections; 16.0%), intra-abdominal
infections (four infectious diarrhea; 16.0%), bacteremia (three
infections; 12.0%), and UTI (two infections; 2.0%).
The etiology of infection could be conﬁrmed in seven cases
(28.0%): Escherichia coli (two UTI and one bacteremia), Staphylo-
coccus aureus (one bacteremia and one soft tissue infection),
Staphylococcus epidermidis (one bacteremia), and Candida albicans
(one cutaneous infection).
The association of different variables with the risk of infection
in patients on the waiting list is shown in Table 2. None of the
variables studied behaved as a statistically signiﬁcant risk factor
for infection in the patients in this study.
Patients with an infection during follow-up did not have a
higher mortality while on the waiting list than those without
infections (mortality in the infection group 13.9% vs. 2.9% for
patients without infection; p = 0.11).
3.2. Immediate post-transplant follow-up
Baseline characteristics of patients who were transplanted and
other aspects concerning the immediate post-transplant period are
summarized in Table 3. After transplant, patients were followed up
for a mean 24.6  11.0 days. The proportion of transplant recipients
who developed an infection in the ﬁrst month after transplantation
was not higher among those who had developed an infection while on
the waiting list (12.5% vs. 23.7% in those without previous infection;
relative risk (RR) 0.50, 95% conﬁdence interval (CI) 0.06–4.00;
p = 0.52). Female sex behaved as a risk factor for early infection after
transplantation (RR 6.99, 95% CI 1.34–36.4; p = 0.02). No other factors
(age, transplantation in urgency code, diabetes, or Charlson
comorbidity index) were associated with a higher frequency of early
infections after transplantation.
Five out of 24 patients (20.8%) died during follow-up after
transplantation. Early mortality after transplantation was higher
in heart transplant recipients who had developed an infection
during the pre-transplant period (50.0% vs. 18.2%), although this
difference was not statistically signiﬁcant (RR 3.83, 95% CI 0.42–
34.8; p = 0.23). No deaths after transplantation were attributed
directly to infection. The need for dialysis after transplantation
(RR 7.68, 95% CI 1.2–46.6; p = 0.027) and a higher CharlsonTable 2
Risk factors for infection in patients awaiting heart transplantation
RR 95% CI p-Value
Sex, male 1.56 0.32–7.59 0.57
Diabetes mellitus 1.96 0.75–5.06 0.16
Age 0.98 0.93–1.03 0.57
Charlson comorbidity index 1.31 0.99–1.73 0.053
Analysis by multivariate Cox regression. RR, relative risk; CI, conﬁdence interval.comorbidity index (RR 1.71, 95% CI 1.0–2.93; p = 0.05) were
associated with higher mortality rates after transplantation.
Recipient age showed a tendency towards a higher mortality (RR
1.1, 95% CI 0.98–1.23; p = 0.09).
4. Discussion
Our results show that infection is a common complication in
patients awaiting heart transplantation. This had not yet been fully
established in heart transplant candidates. Our data indicate that
patients with advanced heart disease awaiting transplantation are
at high risk of infection, although they are generally mild infections
that do not involve increased attributable mortality. In our study,
respiratory infections were the most frequent type of infection.
Respiratory infection is a common complication in patients with
heart failure, and the cause of 60% of all hospital admissions.1 It is
therefore not surprising that respiratory infection is the most
common infectious complication in patients with advanced heart
disease awaiting a heart transplant.
An adequate control of infection in transplant patients must
begin not at the time of transplantation but from the moment the
patient is placed on the waiting list. Transplant candidates often
have chronic terminal deﬁciencies that justify a procedure such as
transplantation. They frequently have comorbidities and have
extensive contact with the healthcare system. The overall clinical
proﬁle of these patients explains in itself the risk of infectious
complications. This explains why it is difﬁcult to ﬁnd speciﬁc risk
factors for infection in these patients, and makes it difﬁcult to
predict who will suffer from an infection.
In our study we found no evidence to suggest that patients with
an infection awaiting heart transplantation are at higher risk of
having another infectious complication in the ﬁrst month after
heart transplantation. The infections found in the immediate post-
transplant period were those expected after surgery (surgical site
infection) and during intensive care of the patient (respiratory tract
infections, catheter-related bacteremia). These infections are
related to surgery and the intensive care management post-
transplantation (mechanical ventilation, central venous catheters),
so previous infections may have no impact on the incidence of
early infections after transplantation. The only risk factor for early
infection that we found in our analysis was female sex. Although it
is widely known that women are at a higher risk for some types of
infections, e.g. UTI15 and wound infection after coronary surgery,16
we have not found female sex described as a risk factor for
infection after heart transplantation in previous publications.
We were not able to demonstrate a worse survival expectancy
after heart transplantation in those patients who had suffered from
an infection before the transplant. Many factors are known to
inﬂuence the post-transplant prognosis in patients undergoing
heart transplantation, such as those recently included in the
IMPACT index17 (Index for Mortality Prediction After Cardiac
Transplantation) – age, race, gender, underlying heart disease, or
need for dialysis – organ ischemic time,17 donor age,17 transplant
urgency,18 and the recipient’s weight prior to transplantation.19 In
our study, the need for dialysis after transplantation, a higher
Charlson comorbidity index, and age (the latter did not reach
statistical signiﬁcance) behaved as risk factors for early mortality.
The existence of such a large number of factors makes it difﬁcult to
determine the true impact of pre-transplant infection as an
independent prognostic factor, suggesting that infection is
probably less important than the factors mentioned above.
We found no other series describing the impact of infection
before heart transplant on the post-transplant period. In a recent
study, Sun et al.20 also found no differences when comparing
mortality at 90 and 180 days after liver transplantation in patients
with and without a history of bacterial infection in the year prior to
Table 3
Characteristics of patients who were transplanted during follow-upa
All transplanted
patients
(n = 24)
Early infection
after transplant
(n = 7)
No early
infection
(n = 17)
p-Value
Age, years 50.8  13.8 51.8  13.9 50.4  14.2 NS
Sex, female 8 (33.3%) 5 (71.4%) 3 (17.6%) 0.021
Diabetes mellitus before transplant 4 (16.7%) 1 (16.7%) 3 (18.8%) NS
Charlson comorbidity index 2.5  1.4 2.3  1.6 2.6  1.4 NS
Need for immunosuppressants before transplant 2 (8.4%) 0 2 (13.3%) NS
Underlying myocardiopathy
Dilated 12 (50%) 4 (57.1%) 9 (52.9%)
Ischemic 5 (20.8%) 2 (28.6%) 3 (17.6%)
Hypertrophic 4 (16.7%) 1 (14.3%) 2 (11.8%)
Congenital 1 (4.2%) 0 1 (5.9%)
Inﬁltrative 1 (4.2%) 0 1 (5.9%)
Retransplant 1 (4.2%) 0 1 (5.9%) NS
Transplant in urgency code 5 (20.8%) 2 (28.6%) 3 (17.6%) NS
Need for dialysis after transplant 4 (16.7%) 1 (16.7%) 3 (18.8%) NS
Organ ischemic time, min 199  47 190  71 203  39 NS
Immunosuppression after transplant NS
Cyclosporine 24 (100%) 7 (100%) 17 (100%)
Steroids 24 (100%) 7 (100%) 17 (100%)
Mycophenolate mofetil 22 (91.6%) 6 (85.7%) 16 (94.1%)
Everolimus 3 (12.5%) 1 (14.2%) 2 (11.7%)
Steroids bolus 4 (16.7%) 2 (28.5%) 2 (11.7%)
Basiliximab 1 (4.2%) 0 1 (5.8%)
Differences were calculated by Mann–Whitney U-test or Fisher’s test. NS, not signiﬁcant.
a Results are mean  standard deviation, or n (%).
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colonization or infection prior to liver transplantation as a
predictor of death in the ﬁrst 3 months after transplantation.
However, in this study no deaths were attributable to infection in
the group of patients presenting infection prior to transplantation.
There are several limitations to our ﬁndings, the main one being
the number of patients included in the study. It is likely that a
larger sample size would have permitted us to obtain signiﬁcant
differences in terms of the prognostic signiﬁcance of infection in
heart transplant candidates.
In conclusion, the frequency of infection in patients awaiting
heart transplant may require collaboration between infectious
disease and transplant specialists from the moment the candidate is
placed on the transplant waiting list. Infections are common in heart
transplant candidates, affecting almost 25% of them. The most
frequent type of infection is respiratory tract infection, followed by
skin and soft tissue infection and infectious diarrhea. However,
infection before heart transplantation is not a risk factor for infection
in the early post-transplant period, as these infections are directly
related to surgery and intensive care management. Moreover,
patients with an infection on the waiting list for heart transplanta-
tion do not have a worse prognosis after transplantation.
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